Visual Outcome at 4 Years Following Plaque Radiotherapy and Prophylactic Intravitreal Bevacizumab (Every 4 Months for 2 Years) for Uveal Melanoma: Comparison With Nonrandomized Historical Control Individuals

Macular DiseasesOcular OncologyRetinal Diseases

Nomogram for visual acuity outcome after iodine-125 plaque radiotherapy and prophylactic intravitreal bevacizumab for uveal melanoma in 1131 patients

Br J Ophthalmol.

Dalvin LA, Zhang Q, Hamershock RA, Chang M, Yu MD, Mashayekhi A, Shields CL

doi: 10.1136/bjophthalmol-2019-314686.

Ocular Oncology

Impact of uveal melanoma thickness on post-plaque radiotherapy outcomes in the prophylactic anti-vascular endothelial growth factor era in 1131 patients

Clin Exp Ophthalmol.

Yang X, Dalvin LA, Mazloumi M, Chang M, Shields JA, Mashayekhi A, Shields CL

doi: 10.1111/ceo.13758.

Ocular Oncology

Visual Outcome and Millimeter Incremental Risk of Metastasis in 1780 Patients With Small Choroidal Melanoma Managed by Plaque Radiotherapy

JAMA Ophthalmol.

Shields CL, Sioufi K, Srinivasan A, DiNicola M, Masoomian B, Barna LE, Bekerman VP, Say EAT, Mashayekhi A, Emrich J, Komarnicky L, Shields JA

doi: 10.1001/jamaophthalmol.

Ocular Oncology

Fractionated stereotactic radiotherapy for uveal melanoma: Long-term outcome and control rates

Acta Ophthalmol

van Beek JGM, van Rij CM, Baart SJ, Yavuzyigitoglu S, Bergmann MJ, Paridaens D, Naus NC, Kiliç E

doi: 10.1111/aos.15029

Macular Diseases

Intravitreal aflibercept for neovascular age-related macular degeneration in patients aged 90 years or older: 2-year visual acuity outcomes

Eye (Lond).

Chatziralli I, Regan SO, Mohamed R, Talks J, Sivaprasad S; UK Aflibercept Users Group.

doi: 10.1038/s41433-018-0114-3.

COMMENTED

Macular Diseases

Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of on-demand therapy every 4 or 8 weeks

Acta Ophthalmol.

Amarakoon S, Martinez-Ciriano JP, van den Born LI, Baarsma S, Missotten T

doi: 10.1111/aos.13774.

Macular DiseasesRetinal Diseases

Baseline Predictors for Five-Year Visual Acuity Outcomes in the Comparison of AMD Treatment Trials

Ophthalmol Retina.

Ying GS, Maguire MG, Pan W, Grunwald JE, Daniel E, Jaffe GJ, Toth CA, Hagstrom SA, Martin DF; CATT Research Group

doi: 10.1016/j.oret.2017.10.003.

Ocular Oncology

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition

Eur J Cancer.

Heppt MV, Heinzerling L, Kähler KC, Forschner A, Kirchberger MC, Loquai C, Meissner M, Meier F, Terheyden P, Schell B, Herbst R, Göppner D, Kiecker F, Rafei-Shamsabadi D, Haferkamp S, Huber MA, Utikal J, Ziemer M, Bumeder I, Pfeiffer C, Schäd SG, Schmid-Tannwald C, Tietze JK, Eigentler TK, Berking C

doi: 10.1016/j.ejca.2017.05.038.

RECOMMENDED

Ocular Oncology

Photodynamic Therapy for Choroidal Metastasis Tumor Control and Visual Outcomes in 58 Cases: The 2019 Burnier International Ocular Pathology Society Lecture

★ 2 Recommended by Prof. Dr Daniel Barthelmes, Faculty Member

Ophthalmol Retina.

Shields CL, Khoo CTL, Mazloumi M, Mashayekhi A, Shields JA

doi: 10.1016/j.oret.2019.10.009.

Related content

Nomogram for visual acuity outcome after iodine-125 plaque radiotherapy and prophylactic intravitreal bevacizumab for uveal melanoma in 1131 patients

Impact of uveal melanoma thickness on post-plaque radiotherapy outcomes in the prophylactic anti-vascular endothelial growth factor era in 1131 patients

Visual Outcome and Millimeter Incremental Risk of Metastasis in 1780 Patients With Small Choroidal Melanoma Managed by Plaque Radiotherapy

Fractionated stereotactic radiotherapy for uveal melanoma: Long-term outcome and control rates

Intravitreal aflibercept for neovascular age-related macular degeneration in patients aged 90 years or older: 2-year visual acuity outcomes

Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of on-demand therapy every 4 or 8 weeks

Baseline Predictors for Five-Year Visual Acuity Outcomes in the Comparison of AMD Treatment Trials

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition

Photodynamic Therapy for Choroidal Metastasis Tumor Control and Visual Outcomes in 58 Cases: The 2019 Burnier International Ocular Pathology Society Lecture